Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)

NCT03283956 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT03283956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Unknown status
Start date
September 13, 2017
Completion date
August 31, 2018
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoembolization, therapeutic, hepatocellular carcinoma non-resectable